Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum

Jared J. Romero,1 Alfredo Q. Antoniazzi,1,2 Natalia P. Smirnova,1 Brett T. Webb,1,3 Fang Yu,4 John S. Davis,5 and Thomas R. Hansen1

1Animal Reproduction and Biotechnology Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; 2Departamento de Clinica de Grandes Animais, Centro de Ciências Rurais, Universidade Federal de Santa Maria, Brazil; 3Veterinary Diagnostic Laboratory, North Dakota State University, Fargo, North Dakota; 4College of Public Health, University of Nebraska Medical Center, and 5VA Medical Center and Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha, Nebraska

Submitted 17 May 2013; accepted in final form 17 September 2013

A better understanding of the mechanisms underlying establishment and loss of pregnancy may be applied to antiluteolytic mechanisms in ovine corpus luteum. Physiol Genomics 45: 1095–1108, 2013. First published September 17, 2013; doi:10.1152/physiolgenomics.00082.2013.—The hypothesis that ovine luteal gene expression differs due to pregnancy status and day of estrous cycle was tested. RNA was isolated from corpora lutea (CL) on days 12 and 14 of the estrous cycle (NP) or pregnancy (P) and analyzed with the Affymetrix bovine microarray. RNA also was isolated from luteal cells on day 10 of estrous cycle that were cultured for 24 h with luteolytic hormones (OXT and PGF) and secretory products of the conceptus (IFNT and PGE2). Differential gene expression (≥1.5-fold, \( P < 0.05 \)) was confirmed using semiquantitative real-time PCR. Serum progesterone concentrations decreased from day 12 to day 15 in NP ewes (\( P < 0.05 \)) reflecting luteolysis and remained >1.7 ng/ml in P ewes reflecting rescue of the CL. Early luteolysis (days 12–14) was associated with differential expression of 683 genes in the CL, including upregulation of SERPINE1 and THBS1. Pregnancy on day 12 (55 genes) and 14 (734 genes) also was associated with differential expression of genes in the CL, many of which were ISGs (i.e., \( ISG15, MX1 \)) that were induced when culturing luteal cells with IFNT, but not PGE2. Finally, many genes, such as \( PTX3, IL6, VEGF, \) and \( LHR \), were stabilized during pregnancy and downregulated during the estrous cycle and in response to culture of luteal cells with luteolytic hormones. In conclusion, pregnancy circumvents luteolytic pathways and activates or stabilizes genes associated with interferon, chemokine, cell adhesion, cytoskeletal, and angiogenic pathways in the CL.

interferon; corpus luteum; progesterone; luteolysis; pregnancy

Address for reprint requests and other correspondence: T. R. Hansen, Animal Reproduction and Biotechnology Lab., Dept. of Biomedical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State Univ., 1683 Campus Delivery, Ft. Collins, CO 80523-1683.
and pregnancy (P) in ewes using the bovine Affymetrix microarray, determining major activated pathways in response to progesterone and early luteolysis and comparing luteal gene expression during the estrous cycle and early pregnancy with responses induced by PGF and OXT, as well as IFNT and PGE2 in cultured luteal cells.

MATERIALS AND METHODS

Animal care and collection of CL and blood samples. All experiments using sheep were reviewed and approved by the Colorado State University Animal Care and Use Committee. Western range ewes purchased from a local producer were either exposed to a vasectomized ram (P group) or not (NP group, no semen exposure) or mated to a fertile ram (P group) to generate CL derived from the estrous cycle or pregnancy, respectively (day 0 = day of estrus). CL were collected during necropsy: day 12 (n = 4 NP and 4 P), day 13 (n = 5 NP and 5 P), day 14 (n = 5 NP and 6 P), day 15 (n = 6 NP and 10 P), and day 16 (n = 5 P). The CL had regressed by day 16 of the estrous cycle and for this reason was not examined. Presence of a conceptus was confirmed by visual identification following flushing the uterine lumen with sterile saline solution at necropsy.

Progesterone assay. Blood samples were collected two times per day starting on day 12, processed to yield serum, and then analyzed for progesterone concentrations with radioimmunoassay (54). The sensitivity of the assay was 15 pg/ml. The mean intra-assay coefficient of variation (CV) was 5.83%. Three quality controls were examined in duplicate for each assay. The CVs were calculated for each standard used in the assay and presented as an average CV for the assay.

RNA isolation. Total RNA was extracted from CL by TRizol Reagent (MRC, Cincinnati, OH) protocol. RNase-free DNase and RNaseMinElute Cleanup Kits (Qiagen) were used to digest DNA and purify RNA. RNA was quantified with a NanoDrop (NanoDrop Technologies, Valencia, CA). Purity of RNA was determined by A260/280 and A260/230 ratios. Proper ratios were between 1.75 and 2.0. RNA integrity was determined with an Agilent 2100 Bioanalyzer.

Analysis of gene microarray data. Microarray analysis was completed at the Microarray Core Facility at the University of Nebraska Medical Center (Dr. Xiaoying Hou). The cDNA probes were synthesized from 200 ng of CL mRNA representing day 12 and 14 of the estrous cycle or pregnancy (n = 3 ewes for each day and pregnancy status) and were used to screen 24,000 targets by using the bovine microarray from Affymetrix (Santa Clara, CA). The microarray data were preprocessed with robust multiarray average algorithm for background correction, quartile normalization and gene-level probe set summation (35). Differential expression (P < 0.05) was determined by the LIMMA method (76). These data were further analyzed with the Metacore pathway analysis program from GeneGo (Carlsbad, CA) to identify signal transduction pathways and genes that are impacted by major effects of day and pregnancy status. Genes with a fold change >1.5, P < 0.05, and a control false discovery rate of 0.1 (from at least one comparison) were determined to be differentially expressed and included in this analysis.

Semi-quantitative real-time RT-PCR. Single-stranded cDNA was synthesized from 1 μg of RNA using the iScript cDNA synthesis kit (Bio-Rad Life Science, Hercules, CA). The synthesized cDNA was used as a template for RT-PCR using iQ SYBR Green Supermix (Bio-Rad Life Science). The cDNA samples were amplified in a 384-well plate with oligonucleotide primers specific to the targets (Table 1). Oligonucleotide primers were designed with an annealing temperature of 61°C, single-product melting curves, and consistent amplification efficiencies (Table 1). Amplification of PCR products was performed at 95°C for 30 s, 61°C for 30 s, and 72°C for 15 s and repeated over 40 cycles. Amplification of cDNA was normalized with the geometric mean of GAPDH, POLR2A, RPL19, and RN18s as internal standards. CT values were analyzed, whereas relative expression of RT-PCR products were plotted using mean 2−ΔΔCT; RT-PCR amplification efficiencies were between 1.8 and 2.2 (72). Ampiclon size was verified through PCR amplification and gel electrophoresis; all amplicons were sequenced to confirm identity with targeted genes.

Culture of isolated SLC, LLC, and mixed luteal cells. Luteal cells were isolated from CL collected from adult western range ewes on day 10 of the estrous cycle; SLC and LLC were separated by elutriation (17). Cells were cultured in six-well plates at the following concentrations: SLC, 2 × 10^5/ml; LLC, 5 × 10^5/ml, and mixed luteal cells (MLC), 1 × 10^6/ml luteal cells. Isolated luteal cell populations were cultured for 24 h at 37°C and 5% CO2 in M199 medium supplemented with 10% FBS and 1% penicillin-streptomycin. After 24 h incubation, the medium was replaced with serum-free medium, and luteal cells were not treated (control) or treated with ISG15 recombinant ovine roIFNT (1 ng/ml, 10^4 U/mg; from Dr. Fuller Bazer, Texas A&M University) or 2 progesterin (P2, 3.5 ng/ml; Sigma Aldrich, Milwaukee, WI). In addition to roIFNT and PGE2, SLC were also treated with OXT [10 μg/ml; Sigma Aldrich, St. Louis, MO (11)], and LLC were treated with PGE2 (11) (3.5 ng/ml; Fisher Scientific, Houston, TX). All cells were treated with IFNT and PGE2 to study genes that were upregulated based on microarray in CL from pregnant ewes. PGE2 was tested in these experiments because it has been described as a luteotrophic agent (29, 43, 63, 69). PGF binds receptors on LLC and OXT binds receptors on SLC to induce luteolysis (55), thus these luteolytic hormones were tested so that genes regulated in response to luteolysis could be examined. Luteal cell mRNA was isolated following 24 h culture with treatments with Trizol reagent. Concentrations of OXT, PGE2, and IFNT were selected based on previous reports of effectiveness in inducing an in vitro response (11). Amount of roIFNT (1 ng/ml) added to luteal cells was determined by a concentration-dependent induction of ISG15 described by Antoniazzi et al. (1) and represented the lowest concentration that required to induce a maximal ISG15 response.

Table 1. Oligonucleotide primer sequences and efficiency of amplification by using semi-quantitative RT-PCR

<table>
<thead>
<tr>
<th>Gene Target</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>RT-PCR Efficiency (1.8–2.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SERPINE1</td>
<td>5’TGATGCGCCAACTCTTCTCAGG3’</td>
<td>5’TGACGAGCTGAACCTGGCTCT3’</td>
<td>2.13</td>
</tr>
<tr>
<td>THBS1</td>
<td>5’ACTGGGTTGTTACGCAAGAG3’</td>
<td>5’CAAGGCGTTATATGTCGAT3’</td>
<td>2.18</td>
</tr>
<tr>
<td>ISG15</td>
<td>5’GGATCTCCCTGCTTGAAGCTT3’</td>
<td>5’ACCTCTCCCTGCTTGAAGCTT3’</td>
<td>1.96</td>
</tr>
<tr>
<td>MX1</td>
<td>5’TGTCTCCCAATGGCTGCTTG3’</td>
<td>5’TCTGAACACTGCTGCTTG3’</td>
<td>2.00</td>
</tr>
<tr>
<td>IL6</td>
<td>5’TGCGAGTGGCCGCTGCTGAG3’</td>
<td>5’CCACTCGGAGCTGCTGAG3’</td>
<td>2.04</td>
</tr>
<tr>
<td>PTX3</td>
<td>5’TGTGCTGCTTCTTCCGAGT3’</td>
<td>5’CTGCTGCTGCTGCTGAGT3’</td>
<td>2.00</td>
</tr>
<tr>
<td>VEGF</td>
<td>5’TGTGCTGCTTCTTCCGAGT3’</td>
<td>5’ACCTGCTGCTGCTGAGT3’</td>
<td>2.06</td>
</tr>
<tr>
<td>LHR</td>
<td>5’TGTGCTGCTTCTTCCGAGT3’</td>
<td>5’CTGCTGCTGCTGCTGAGT3’</td>
<td>1.92</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5’TGACGCGCTCTGCTGCTGCTT3’</td>
<td>5’GCTGCGCTCTGCTGCTGCTT3’</td>
<td>1.95</td>
</tr>
<tr>
<td>POLR2A</td>
<td>5’AGACCTCAAGTCCGCTGCTGAGT3’</td>
<td>5’AGACCTCAAGTCCGCTGCTGAGT3’</td>
<td>2.04</td>
</tr>
<tr>
<td>RPL19</td>
<td>5’TGGGCTGCTTCTGCTGCTGAGT3’</td>
<td>5’GGGCTGCTTCTGCTGCTGAGT3’</td>
<td>2.20</td>
</tr>
<tr>
<td>RN18S</td>
<td>5’GAGGCGCTGCTTCTGCTGAGT3’</td>
<td>5’GACAGCAATTTATACGCTGATG3’</td>
<td>2.20</td>
</tr>
</tbody>
</table>
genes were differentially expressed in CL collected from NP compared with P ewes. As the estrous cycle progressed from day 12 to 14, which also corresponded with the onset of luteolysis in response to endogenous PGF, there were 683 differentially expressed genes. As pregnancy progressed from day 12 to 14, there were 21 differentially expressed genes in P ewes. On day 14, there were 734 differentially expressed genes in CL from P compared with NP ewes.

Pathway analysis. Because there were only 55 differentially expressed genes on day 12 in NP compared with P ewes and 21 differentially expressed genes as pregnancy progressed from day 12 to 14, pathway analysis was limited but implicated pregnancy-associated immune response and IFN alpha/beta signaling, as well as steroid biosynthesis and cytoskeletal remodeling in the CL (Tables 2 and 3). Key pathways identified in CL from day 14 P compared with NP ewes were: cell adhesion, chemokines [interleukin 8 (IL-8)], cytoskeletal remodeling and transforming growth factor (TGF) beta signaling \((P < 0.0001, 8–21\) genes; Table 4). Genes differentially expressed as the CL entered early stages of luteolysis from day 12 to 14 NP belonged to cell cycle, adhesion, chemokine (IL-8), TGF-β, and cytoskeleton pathways \((P < 0.0001, 10–21\) genes; Table 5).

Selection of the differentially expressed genes for further study was based on representation in the pathway analysis, but also on significance and fold change from the microarray analysis data (Table 6). The eight genes selected for further analysis were: serpine peptidase inhibitor (SERPINE1), thrombospordin 1 (THBS1), ISG15, myxovirus (influenza virus) resistance 1 (MX1), IL6, pentraxin 3 long (PTX3), vascular endothelial growth factor A (VEGF), and luteinizing hormone/choriogonadotropin receptor (LHR). We also examined genes that have been implicated previously in the CL in processes such as [steroidogenesis steroid acute regulatory protein (STAR), peripheral benzodiazepine receptor (PBR), P450 sidechain cleavage (CYP11A1), and 3β-hydroxysteroid dehydrogenase (3βHSD)], and prostaglandin biosynthesis and action [hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD), PTGS2, prostaglandin F synthase (PGFS), and prostaglandin E synthase (PTGES)] to determine if they were differentially expressed in the CL in response to pregnancy or luteolysis based on microarray analysis (Table 6). STAR, CYP11A1, and 3βHSD mRNA concentrations were downregulated reflecting decline in production of progesterone from days 12 to 14 of the estrous cycle. These steroidogenic proteins also were downregulated on day 14 of the estrous cycle compared with pregnancy (Table 6). PBR and the prostaglandin biosynthesis enzyme mRNA concentrations did not change during the estrous cycle or pregnancy.

Microarray and RT-PCR validation of gene targets. Genes upregulated in the CL during early stages of luteolysis

---

Table 2. The top pathways in CL on day 12 of NP compared with P in ewes

<table>
<thead>
<tr>
<th>Pathway 12NP/12P</th>
<th>(P) Value</th>
<th>Genes in Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\Delta508)-CFTR traffic/ER to Golgi in CF</td>
<td>0.02</td>
<td>2/13</td>
</tr>
<tr>
<td>Normal wtCFTR traffic/ER to Golgi</td>
<td>0.02</td>
<td>2/13</td>
</tr>
<tr>
<td>Cell cycle initiation of mitosis</td>
<td>0.07</td>
<td>2/25</td>
</tr>
<tr>
<td>Cytoskelton remodeling fibronectin-binding integrins in cell motility</td>
<td>0.08</td>
<td>2/28</td>
</tr>
</tbody>
</table>

CL, corpus luteum; NP, estrous cycle (nonpregnant); P, pregnant; CFTR, cystic fibrosis transmembrane conductance regulator; CF, cystic fibrosis.
based on microarray data were SERPINE and THBS1 (Fig. 2). SERPINE1 \((P < 0.05)\) and THBS1 \((P < 0.01)\) were affected by pregnancy in the model and increased in CL from NP compared with P ewes on day 14. Neither SERPINE1 nor THBS1 mRNA concentrations changed very much during days 12–15 of pregnancy. However, after day 15, THBS1 mRNA concentrations tended \((P < 0.10)\) to increase.

Genes upregulated in response to pregnancy based on microarray analysis were ISG15 and MX1 (Fig. 3). ISG15 and MX1 mRNA concentrations did not change during the estrous cycle. However, by day 15 of pregnancy, mRNA concentrations increased and continued to increase through day 16 of pregnancy.

Genes stabilized during pregnancy and downregulated in response to luteolysis were IL6 \((P < 0.05)\), PTX3 \((P < 0.001)\), LHR \((P = 0.05)\), and VEGF \((P < 0.05);\) Fig. 4, A and B. IL6 and PTX3 mRNA concentrations were downregulated as early as day 14 and remained downregulated through day 15 of the estrous cycle. LHR and VEGF were downregulated by day 15 of the estrous cycle. All of these genes were stabilized during pregnancy, and in one case, LHR, there was a tendency \((P < 0.10)\) for upregulation in mRNA concentrations by day 16 of pregnancy.

Culture of SLC, LLC, and MLC. SERPINE1 mRNA concentrations increase transiently during luteolysis (Fig. 2), and for this reason it was examined in cultured luteal cells (Fig. 5). Isolated SLC and LLC had similar SERPINE1 mRNA concentrations regardless of treatments in vitro. While IFNT had no effect, PGE2, PGF, and OXT tended \((P < 0.10)\) to decrease SERPINE1 mRNA concentrations when cultured with MLC.

Culture of SLC, LLC, and MLC with IFNT caused massive induction of ISG15 (Fig. 5B), which was consistent with the response of the CL to pregnancy based on microarray and RT-PCR data. Culture of luteal cells with PGE2 had no impact on ISG15 mRNA concentrations. Likewise, culture of SLC and LLC with PGF and OXT had no effect on ISG15 mRNA concentrations. In contrast, culture of MLC luteal cells with PGF and OXT caused downregulation of ISG15 mRNA concentrations compared with control cultures.

IL6 mRNA concentrations did not change in cultured isolated SLC and LLC (Fig. 5C). In MLC, PGF and OXT caused downregulation of IL6, whereas culture with IFNT and PGF had no effect. Interestingly, this same general trend in downregulation by culture with PGF and OXT in MLC with no effect in isolated SLC and LLC was the same for PTX3 (Fig. 6A) and VEGF (Fig. 6C) mRNA concentrations. A tendency \((P < 0.10)\) for downregulation of LHR mRNA concentrations following culture of SLC with OXT, and LLC with PGF was supported by significant \((P < 0.05)\) downregulation of LHR mRNA concentrations following culture of MLC with PGF and OXT (Fig. 6B). Interestingly, culture of only LLC with IFNT caused an upregulation of LHR and a tendency \((P < 0.08)\) for upregulation of VEGF mRNA concentrations, whereas there was no effect of IFNT in cultured SLC or MLC.

**DISCUSSION**

Establishment of early pregnancy in sheep is mediated through conceptus-derived IFNT and paracrine inhibition of upregulation of ESR1 and OXTR that occurs in the endometrium during the estrous cycle (77). In addition to this well-described paracrine action, an endocrine role for IFNT has been suggested based on detection of antiviral activity in uterine vein blood (59). Confirmation that IFNT is present in uterine vein blood was based on inhibition of antiviral activity following preadsorption with antibody against IFNT (6) and detection of IFNT by radioimmunoassay (1) and mass spectrometry approaches (Romero JJ and Hansen TR, unpublished results). Indirect evidence to support endocrine action of IFNT provided herein and reported previously (6, 59) is based on upregulation of ISGs in the CL in response to pregnancy and IFNT. Likewise, systemic infusion of roIFNT for 24 h protects the CL against a subluteolytic challenge with PGF (1) when administered on day 10 of the estrous cycle. However, to our knowledge, IFNT has never been detected in systemic blood during pregnancy in ruminants. The present experiments studied systemic impact of early pregnancy in sheep on the CL and

<table>
<thead>
<tr>
<th>Pathway 14P/12P</th>
<th>(P) Value</th>
<th>Genes in Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Androstenedione and testosterone biosynthesis and metabolism p.2</td>
<td>0.03</td>
<td>2/17</td>
</tr>
<tr>
<td>2. Androstenedione and testosterone biosynthesis and metabolism p.2 rodent version</td>
<td>0.03</td>
<td>2/18</td>
</tr>
</tbody>
</table>

Table 3. The top pathways in CL from days 12 to 14 of P in ewes

<table>
<thead>
<tr>
<th>Pathway 14NP/14P</th>
<th>(P) Value</th>
<th>Genes in Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cell adhesion chemokines and adhesion</td>
<td>(1 \times 10^{-6})</td>
<td>20/93</td>
</tr>
<tr>
<td>2. Cytoskeleton remodeling</td>
<td>(2 \times 10^{-6})</td>
<td>20/96</td>
</tr>
<tr>
<td>3. TGF, WNT, and cytoskeletal remodeling</td>
<td>(4 \times 10^{-6})</td>
<td>21/107</td>
</tr>
<tr>
<td>4. Development TGF-β-dependent induction of EMT via MAPK</td>
<td>(4 \times 10^{-6})</td>
<td>13/46</td>
</tr>
<tr>
<td>5. Cell adhesion plasmin signaling</td>
<td>(6 \times 10^{-6})</td>
<td>11/34</td>
</tr>
<tr>
<td>6. Development TGF-β-dependent induction of EMT via Smads</td>
<td>(5 \times 10^{-5})</td>
<td>10/35</td>
</tr>
<tr>
<td>7. Cell adhesion ECM remodeling</td>
<td>(8 \times 10^{-5})</td>
<td>12/51</td>
</tr>
<tr>
<td>8. Development role of IL-8 in angiogenesis</td>
<td>(2 \times 10^{-4})</td>
<td>11/47</td>
</tr>
<tr>
<td>9. Development regulation of EMT</td>
<td>(2 \times 10^{-4})</td>
<td>13/63</td>
</tr>
<tr>
<td>10. Cytoskeleton remodeling, fibronectin-binding integrins in cell motility</td>
<td>(3 \times 10^{-4})</td>
<td>8/28</td>
</tr>
</tbody>
</table>

TGF, transforming growth factor; WNT, wingless-type MMTV integration site family; EMT, epithelial-to-mesenchymal transition.
further examined the hypothesis that pregnancy induces genes, including ISGs that contribute to survival of the CL and resistance of the CL to luteolysis. Differential CL gene expression in response to early stages of luteolysis also was examined.

**Validation of animal model.** Serum progesterone concentrations were the same regardless of pregnancy status on days 12 and 13. For this reason, collection and analysis of CL on these days provides an excellent reference point in context of representation of a viable CL that is producing progesterone. By day 14 of the estrous cycle, serum progesterone concentrations were declining, and by day 15 of the estrous cycle serum progesterone had reached concentrations that were significantly lower and representative of luteolysis compared with days 12 and 13 of the estrous cycle and days 14–15 of pregnancy. Rather than focusing on day 15, which represented endpoint responses of the CL to luteolysis, we collected CL on day 14 of the estrous cycle and pregnancy to focus on early stages of luteolysis and maternal recognition of pregnancy. However, by also implementing RT-PCR, a larger sample (ewe) size and representations were the same regardless of pregnancy status on days 12, 13, and 14, which represented endpoint responses of

**Early mediators of luteolysis.** One of the proteins that is believed to be involved with the extensive extracellular matrix remodeling of the CL during its formation and regression is SERPINE1 (PAL-1) (74). SERPINE1 mRNA concentrations have not been shown to change in CL during the ovine estrous cycle on days 3, 7, 10, 13, and 16 (74). However, in the present studies, SERPINE1 mRNA concentrations increased transiently from days 13 to 14 and then declined by day 15. This transient increase in SERPINE1 also was described by others in the ovine CL within 6 h following in vivo treatment with PGF (74). Exactly why SERPINE1 mRNA concentrations increase transiently during the late estrous cycle and in response to PGF in vivo is unknown but might be related to preparing the extracellular matrix of the CL for luteolysis. A balance of remodeling of extracellular matrix may be achieved through this transient increase in this inhibitor of plasminogen activator. For example, in the bovine CL, SERPINE1 and other plasminogen activators such as urokinase-type plasminogen activator, uPA receptor, and tissue-type PA have been shown to change in CL during the estrous cycle on days 3, 7, 10, 13, and 16 (74).

### Table 5. The top 10 pathways in CL during early luteolysis on days 12–14 of NP in ewes

<table>
<thead>
<tr>
<th>Pathway</th>
<th>14NP/12NP</th>
<th>P Value</th>
<th>Genes in Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cell cycle spindle assembly and chromosome separation</td>
<td>3 × 10⁻⁶</td>
<td>11/32</td>
<td></td>
</tr>
<tr>
<td>2. Cell adhesion chemokines and adhesion</td>
<td>5 × 10⁻⁶</td>
<td>19/93</td>
<td></td>
</tr>
<tr>
<td>3. Development TGF-β-dependent induction of EMT via SMADs</td>
<td>7 × 10⁻⁶</td>
<td>11/35</td>
<td></td>
</tr>
<tr>
<td>4. Cytoskeleton remodeling</td>
<td>8 × 10⁻⁶</td>
<td>19/96</td>
<td></td>
</tr>
<tr>
<td>5. TGF, WNT, and cytoskeletal remodeling</td>
<td>1 × 10⁻⁶</td>
<td>20/107</td>
<td></td>
</tr>
<tr>
<td>6. Cell cycle chromosome condensation in prometaphase</td>
<td>2 × 10⁻⁸</td>
<td>8/20</td>
<td></td>
</tr>
<tr>
<td>7. Development TGF-β-dependent induction of EMT via MAPK</td>
<td>2 × 10⁻⁸</td>
<td>12/46</td>
<td></td>
</tr>
<tr>
<td>8. Development role of IL-8 in angiogenesis</td>
<td>3 × 10⁻⁸</td>
<td>12/47</td>
<td></td>
</tr>
<tr>
<td>9. Cytoskeleton remodeling fibronectin-binding integrins in cell motility</td>
<td>4 × 10⁻⁸</td>
<td>9/28</td>
<td></td>
</tr>
<tr>
<td>10. Development regulation of EMT</td>
<td>1 × 10⁻⁴</td>
<td>13/63</td>
<td></td>
</tr>
</tbody>
</table>

### Table 6. Genes selected from microarray analysis that were differentially expressed in the CL in response to day or in response to pregnancy status

<table>
<thead>
<tr>
<th>Gene Targets</th>
<th>Day 12 P vs. NP</th>
<th>Day 14 P vs. 12 P</th>
<th>Day 14 NP vs. 12 NP</th>
<th>Day 14 P vs. NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>SERPINE1</td>
<td>NS</td>
<td>21.3 5.4 × 10⁻¹¹</td>
<td>−16.8 1 × 10⁻¹⁰</td>
<td>NA</td>
</tr>
<tr>
<td>THBS1</td>
<td>NS</td>
<td>4.09 2 × 10⁻⁶</td>
<td>−4.06 3 × 10⁻⁶</td>
<td>NA</td>
</tr>
<tr>
<td>ISG15</td>
<td>NS</td>
<td>2.3 0.022</td>
<td>3.1 0.004</td>
<td>NA</td>
</tr>
<tr>
<td>MX1</td>
<td>1.5 0.035</td>
<td>1.35 0.096</td>
<td>2.2 0.005</td>
<td>NA</td>
</tr>
<tr>
<td>IL-6</td>
<td>NS</td>
<td>−6.8 0.0007</td>
<td>4.4 0.0045</td>
<td>NA</td>
</tr>
<tr>
<td>PTV3</td>
<td>NS</td>
<td>−4.1 0.0016</td>
<td>3.6 0.0016</td>
<td>NA</td>
</tr>
<tr>
<td>VEGF</td>
<td>NS</td>
<td>−2.7 3 × 10⁻⁵</td>
<td>3.4 4 × 10⁻⁶</td>
<td>NA</td>
</tr>
<tr>
<td>LHCGR</td>
<td>NS</td>
<td>−2.2 0.0002</td>
<td>2.1 0.0004</td>
<td>NA</td>
</tr>
<tr>
<td>STAR</td>
<td>NS</td>
<td>−1.62 0.0001</td>
<td>1.7 5 × 10⁻⁵</td>
<td>NA</td>
</tr>
<tr>
<td>PBR</td>
<td>NA</td>
<td>−1.58 0.015</td>
<td>1.4 0.001</td>
<td>NA</td>
</tr>
<tr>
<td>CYP11A1</td>
<td>NS</td>
<td>−1.7 0.0009</td>
<td>1.7 0.001</td>
<td>NA</td>
</tr>
<tr>
<td>HSD3B</td>
<td>NS</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>PTGS2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>PGFS</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>PTGES</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>TGFB</td>
<td>−1.27 0.013</td>
<td>1.69 4 × 10⁻⁵</td>
<td>−1.68 4 × 10⁻⁵</td>
<td>NA</td>
</tr>
<tr>
<td>IL8</td>
<td>1.19 0.06</td>
<td>−1.48 0.0004</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA, genes that have a role in CL function but are nonapplicable because they were not shown to be differentially expressed in the microarray data; NS, nonsignificant microarray genes within noted comparison that were different within other comparisons.
When examined in cultured luteal cells, SERPINE1 mRNA concentrations did not change in isolated SLC and LLC. However, in MLC there was a tendency for downregulation of SERPINE1 mRNA concentrations following 24 h culture with PGE2, PGF, and OXT. Smith and coworkers (74) described a transient increase in SERPINE1 mRNA concentrations within 6 h following in vivo treatment with PGF. Whether this early rapid increase in SERPINE1 mRNA concentrations also occurs following treatment of MLC with PGF in vitro remains to be determined. Also, the reason for tendency in SERPINE1 mRNA concentrations to be suppressed following treatments in vitro, while concentrations are transiently increased on day 12 of the estrous cycle, remains to be determined.

This transient increase in CL SERPINE1 mRNA concentrations on day 14 of the estrous cycle was very similar to the profile of THBS1 mRNA concentrations in the CL during the estrous cycle. THBS1 increased as early luteolysis progressed in CL from day 12 to 14 of the estrous cycle. THBS1 is a secreted extracellular matrix glycoprotein that has been shown to be involved in platelet activation, cell adhesion, cell-to-cell and cell-to-matrix communication, promotion, and inhibition of angiogenesis and tissue healing (16, 42, 47). THBS1 induces TGFβ (68), which also was upregulated 1.7-fold (P < 0.005) in the CL during the estrous cycle (see supplemental microarray files). Previous studies in the cow demonstrate that PGF induces luteal expression of TGFβ (32, 50), which may contribute to functional and structural regression of the CL (46). TGFβ induces SERPINE1 gene expression (90). Thus, THBS1 may cause upregulation of SERPINE1 through the TGFβ pathway.

The antiangiogenic properties of THBS1 have been shown in several studies (42, 49). Zalman et al. (88) demonstrated that endothelial and steroidogenic cells of the CL express abundant concentrations of THBS1 mRNA. THBS1 has been shown to bind as well as sequester proangiogenic factors such as VEGF, which was stabilized in the present studies in CL during pregnancy and might be associated with luteal resistance (25, 45). THBS1 promotes the internalization of VEGF by low-density lipoprotein receptor-related protein-1 in nonendothelial cells and partially suppresses VEGF expression in those cells (23). The effects of THBS1 on endothelial cells result in cell cycle arrest, repressed motility, chemotaxis, and increased apoptosis (2, 24, 36, 68). In the bovine CL, Zalman and coworkers (88) also demonstrated that PGF induces THBS1 in MLC and suggested that it may be involved in luteolysis. THBS1 has been shown to cause apoptosis in endothelial cells; thus it may act in a similar manner in the CL.

THBS1 may cause apoptosis by activation of the CD36/p59fyn/caspase-3/p38MAPK cascade in endothelial cells. Antibodies against THBS1 can block apoptotic activation through neutralizing THBS1 or preventing access of THBS1 to CD36 (36). THBS1 action can also be blocked by compounds that inhibit p38MAPK or caspase-3-like proteases (36). THBS1 upregulates the cytokines FasL and TNF (66) and Bax (58), which are known mediators of apoptosis. In this regard, TNF induces apoptosis of bovine endothelial cells (30, 64). Because THBS1 is upregulated in CL on day 14 of the estrous cycle, is
induced by PGF, and has antiangiogenic and proapoptotic properties, it may have a critical role in the demise of the CL.

**Uptregulation of pregnancy-associated genes in the CL: ISGs.** Pregnancy induces several ISGs in the endometrium and CL (28). Microarray analysis demonstrated upregulation of several of these ISGs in the CL such as: ISG15 (Fig. 3), MX1 (Fig. 3), MX2, IRF6, IRF9, CCL2, CCL8, IFI44, and OAS in response to pregnancy. ISG15 has been shown to be induced by IFNT in several reproductive tissues, as well as peripheral blood cells (3, 4, 21, 26, 37, 80, 87) and in luteal cells cultured with roIFNT (Fig. 5). While the exact functions of ISG15 in the CL are not known, ISG15 is able to conjugate to and regulate proteins through an enzymatic pathway similar to that described for ubiquitin utilizing the ubiquitin-activating enzyme 1-like protein (67). This IFNT-induced regulation of intracellular proteins by ISG15 may help provide resistance of the CL to lysis by PGF and is the focus of future experiments.

Culture of SLC, LLC, and MLC with roIFNT caused a massive upregulation of ISG15 mRNA concentrations, which is consistent with earlier reports (1, 6, 28, 59). The addition of PGE2 had no impact on ISG15 mRNA concentrations in cultured luteal cells. This is interpreted to suggest that luteotrophic action of PGE2 is not mediated through the ISGs. The suppression of ISG15 mRNA concentrations in MLC after culture with PGF or OXT might reflect damaging effects of these lyric hormones.

**MX1** gene expression is induced in the endometrium by pregnancy, progesterone, and IFNs (α, β, and γ) (22, 62). MX1 is upregulated in the ovine glandular epithelium in response to IFNT released from the conceptus during early pregnancy in ruminants and following in vitro culture of endometrial cells with IFNT (8, 83, 84). MX1 protein concentrations have also been shown to increase in uterine flushings from pregnant ewes after day 15 (83, 84).

In the present experiments, MX1 mRNA concentrations were upregulated in the CL in response to pregnancy as early as day 12 and remained upregulated through day 14 of pregnancy based on the microarray analysis. RT-PCR demonstrated that MX1 mRNA concentrations were significantly greater in the CL on days 15 and 16 in P ewes. Thus, MX1 mRNA concentrations remained elevated in the CL up to and possibly beyond day 16 of pregnancy. MX1 is a GTPase that mediates antiviral responses (31) through a functional GTP binding motif (18). MX1 may also facilitate “nontraditional” secretion of proteins (53, 83) that are distinct from known classical secretion mechanisms via the endoplasmic reticulum and Golgi (61). The function of MX1 in the CL during early pregnancy is unknown but might entail mediating acute immune responses and intracellular GTP-driven mechanisms such as nontraditional release of proteins.

**Pregnancy stabilizes genes that are downregulated in the CL during the estrous cycle.** IL6, PTX3, LHR, and VEGF mRNA concentrations were stabilized in the CL over days 12, 13, 14, 15, and 16 of pregnancy, with a tendency for an increase in LHR mRNA concentrations on day 16 of pregnancy. All of these genes were downregulated by day 14 (IL6 and PTX3) or 15 (LHR and VEGF) of the estrous cycle, which corresponds to the decline in serum progesterone concentrations and luteolysis. In cultured MLC, PGF and OXT caused downregulation of each of these genes compared with controls. This is consistent
A

Gene, Function Pathway, Fold Change

Interleukin 6, IL6.
✓ Maturation of B cells
✓ 14 vs 12 NP: -6.8 fold,
  P < 0.001
✓ 14 P vs NP: 4.4 fold,
  P < 0.05
✓ Immune response pathway

Pentraxin, 3 long, PTX3
✓ Provide resistance to neurodegeneration.
✓ 14 P vs NP: 3.61 fold,
  P < 0.001
✓ 14 vs 12 NP: -4.077 fold,
  P < 0.05
✓ Immune response pathway

B

Gene, Function Pathway, Fold Change

Luteinizing Hormone Receptor, LHR
✓ Binding of LH to its receptor is required for normal CL function and formation.
✓ 14 vs 12 NP: 2.2 fold,
  P < 0.001
✓ 14 P vs NP: 2.1 fold,
  P < 0.0001
✓ Hormone biosynthesis pathway

Vascular endothelial growth factor, VEGF
✓ Necessary for follicular growth, enhancing micro vascular permeability, and inhibiting apoptosis.
✓ 14 vs 12 NP: -1.4 fold,
  P < 0.05
✓ 14 P vs NP: 1.9 fold,
  P < 0.001
✓ Angiogenesis pathway

Fig. 4. Genes stabilized during pregnancy and down-regulated in the CL during luteolysis. Selected genes out of 734 differentially expressed in CL on day 14 of P compared with the NP included IL6 and PTX3 (A) and LHR and VEGF (B). General function, fold changes in mRNA concentrations based on microarray analysis, and implicated pathways are described at left. Factorial analysis of RT-PCR for these mRNAs over days of the NP and P are shown at right. Means represented with different letters differ across days of the estrous cycle (P < 0.05). *Differences (P < 0.05) across pregnancy status on the same day. Tendency (P < 0.10) in differences across pregnancy status on the same day. Values represent means ± SE.
with in vivo data showing downregulation of these genes in the CL as the late estrous cycle progressed. Culture of SLC and MLC with IFNT had no effect on mRNA concentrations for these genes. Interestingly, the MLC model tended to provide greater responses to treatments applied in vitro. This might be explained through interactions in MLC cultures between SLC and LLC, but also with cells in the CL such as endothelial and immune cells. However, in LLC, IFNT upregulated LHR and tended to upregulate VEGF mRNA concentrations. These data are interpreted to mean that pregnancy (i.e., IFNT) stabilizes expression of these genes, which would otherwise become downregulated in response to luteolysis during the estrous cycle. Stabilization of these genes during early pregnancy may contribute to resistance of the CL to luteolysis.

IL6, also known as IFN beta 2, is pro- and anti-inflammatory and pyrogenic and activates B- and T-cells (48). Overexpression of IL6 is associated with several diseases such as rheumatoid arthritis and postmenopausal osteoporosis (52, 81). IL6 has been described in day 15 cultured luteal cells; however, treatment of these cells with progesterone silenced expression of IL6 (82), and IL6 gene expression appears to be silenced in the CL during pregnancy. Pregnancy-associated signals, such as IFNT, may help stabilize IL6 expression in the ovine CL, if progesterone does indeed have inhibitory action. In MLC described herein, culture with PGF and OXT reduced IL6 mRNA concentrations. Stabilization of basal levels of IL6 might be necessary in the CL during early pregnancy. One benefit for continued action of IL6 in the CL is the indirect induction of angiogenesis through inducing VEGF expression (10). VEGF may have a functional role in luteal resistance; therefore IL6 expression could be functioning in luteal resistance and maintenance of the CL by inducing VEGF (see later DISCUSSION). It also could be acting synergistically with IFNT to modulate immune responses in the CL during early pregnancy.

Pentraxins are a superfamily of multifunctional proteins that are highly conserved from arthropods to mammals and expressed by several cell types (7, 12). PTX3 has been shown to be present in follicular fluid and plasma (19). PTX3 expression is upregulated in human stromal cells by progesterone and by trophoblast conditioned medium or trophoblast explants (19).
It also is upregulated in follicular theca and granulosa cells in response to LH (9). PTX3 expression has been shown to provide resistance to neurodegeneration possibly rescuing neurons from irreversible damage (12, 65). PTX3 double-knockout mice have increased myocardial damage suggesting that PTX3 plays a cardioprotective role (71). These two findings indicate that PTX3 may play a protective role in cells undergoing stress and may contribute to the maintenance of pregnancy by protecting the CL. Stabilization of PTX3 in the CL during pregnancy may be relevant in context of cell survival responses designed for protection against apoptosis and autoimmune responses such as those mounted against cell remnants from antigen-presenting cells (70). The idea that PTX3 is stabilized in the CL of pregnancy is further supported by the fact that PTX3 mRNA concentrations were greater during the midluteal phase compared with earlier or later days of the estrous cycle. A decrease in LHR mRNA concentrations were greater during the midluteal phase compared with earlier or later days of the estrous cycle. A decrease in LHR mRNA concentrations by 7.5 h after injection of PGF, which is consistent with decline in LHR mRNA concentrations by day 15 of the estrous cycle in the present studies. The number of occupied, unoccupied and affinity of receptors, and the number of receptors occupied by LH do not change 7.5 h after injection of PGF (13). However, all of these parameters were affected negatively by 22 h following injection of PGF, which is consistent with decline in LHR mRNA concentrations by day 15 of the estrous cycle in the present studies.

LH is required for normal CL function and formation and for the maintenance of the mature CL (38). Infusion of LH has been shown to prolong luteal life (39). Ovine luteal weight, luteal concentration of progesterone, total number of LH receptors, and the number of receptors occupied by LH do not change 7.5 h after injection of PGF (13). However, all of these parameters were affected negatively by 22 h following injection of PGF, which is consistent with decline in LHR mRNA concentrations by day 15 of the estrous cycle in the present studies. The number of occupied, unoccupied and affinity of LH also do not change on days 12, 16, and 20 of pregnancy. This was later confirmed by Zelinski and coworkers (89) when comparing days 13 to 16 of the estrous cycle to pregnancy (14). However, Smith and coworkers (75) demonstrated that LHR mRNA concentrations were greater during the midluteal phase on days 10–13 compared with earlier or later days of the estrous cycle in sheep CL. A decrease in LHR within 6 h after injection of PGF also was described. This concurs with the decline in LHR mRNA concentrations in CL during the late pregnancy phase.
estrus cycle when analyzed herein by microarray and RT-PCR approaches. It also is consistent with the downregulation of LHR mRNA concentrations when MLC were cultured herein for 24 h with PGE2 and OXT.

The primary difference in the present studies compared with those previously reported for LHR in ovine CL during pregnancy is the tendency for upregulation of LHR mRNA concentrations on day 16 of pregnancy and the apparent increase in LHR mRNA concentrations in response to culture of MLC with rolIFNT. An explanation for this discrepancy might be provided by slight differences in actual day of pregnancy and degree of development of the conceptus across these studies. For example, in the present experiments, day 16 of pregnancy might represent a slightly more advanced conceptus and secretary protein (i.e., IFNT) producing capacity.

IFNT has been implicated in lymphangiogenesis in bovine CL through induction of VEGF (57). VEGF is a multifunctional cytokine that is necessary for follicular growth, enhancing microvascular permeability, angiogenesis, ovulation, and development and function of the CL (5, 60) VEGF protein concentrations steadily decrease from early to late stages of luteolysis (5, 60). This is probably caused through direct action of PGF because day 11 luteal cells cultured with PGF have decreased VEGF mRNA concentrations compared with control, untreated cells (88). This also is consistent with enclosed downregulation of VEGF mRNA concentrations following culture of MLC with luteolytic PGF and OXT. In microarray and RT-PCR results described herein, VEGF mRNA concentrations decreased on day 14 and 15 during the estrous cycle, suggesting that PGF causes a decrease in VEGF mRNA concentrations. VEGF gene expression is tightly associated with other genes that were identified in our microarray such as IL6 and THBS1. IL6 mRNA concentrations were associated with pregnancy and correlated with upregulation of VEGF in the CL. THBS1 was associated with luteolysis and with a downregulation in VEGF. VEGF mRNA concentrations in the ovine CL appear to be associated with pregnancy status, are stabilized in the CL during early pregnancy, and tend to be induced, at least in LLC, following culture with IFNT.

Conclusions

In the absence of a conceptus, spontaneous regression of the CL occurs as a consequence of differential expression of at least 683 genes that include cell adhesion, chemokines, cytoskeletal remodeling, and apoptotic pathways. Two of these genes, SERPINE1 and THBS1, were selected for further study and found to be transiently upregulated during the latter part of the estrous cycle and during early luteolysis. These genes may play a role in regulation of the extracellular matrix (33, 40) to facilitate invasion of immune cells and inhibition of the synthesis of progesterone. Future experiments may focus on the TGFB pathway, which had 19 genes differentially expressed during luteolysis and may provide a link between SERPINE1 and THBS1 action in the early regressing CL.

Until recently, early pregnancy was described to be maintained through exclusive paracrine action of the conceptus on the endometrium in ruminants. Based on enclosed microarray data describing differential expression of 55 genes in CL between P and NP ewes on day 12, 21 genes between days 12 and 14 of pregnancy, and 734 genes between P and NP ewes on day 14, it is concluded that pregnancy-associated gene expression occurs in the CL. Several conceptus secretory products might be driving this differential gene expression in the CL, but a primary candidate based on induction of ISGs by pregnancy and through culture of isolated luteal cells is IFNT. This conclusion is supported by upregulation of several ISGs in the CL based on microarray data, two of which, ISG15 and MX1 were more extensively examined in the CL by RT-PCR approaches. Neither of these ISGs was affected by culture of SLC, LLC, or MLC with PGE2, which is interpreted to suggest that luteotropic action of PGE2 is not mediated via ISGs.

The maintenance of a healthy conceptus is a complicated process that involves cell proliferation, differentiation and continued activation of the steroidogenic pathway for continued production of progesterone (IL6, VEGFA, and LHR), as well as regulation of immune responses and activation of interferon signaling (PTX3, ISG15, and MX1). Pregnancy stabilizes ISG15, MX1, IL6, PTX3, LHR, and VEGFA, whereas luteolysis causes downregulation of these genes. Conceptus-derived IFNT maintains/induces IL6, VEGFA, LHR, ISG15, MX1, and PTX3 in vivo. In vitro, PGF and OXT suppressed all of these genes in MLC. In addition to providing protection or resistance of the CL to lytic action of PGF, the endocrine actions of IFNT may prime the maternal innate immune system for more rapid and robust antiviral responses to protect the embryo and early developing fetus from disease or infection.

ACKNOWLEDGMENTS

We express our gratitude to Dr. Hans Mayan for conducting elutriation of luteal cells over the years and to the staff and students at the Animal Reproduction and Biotechnology Laboratory for kind assistance with animal husbandry and surgical and necropsy procedures.

GRANTS

This project was supported by the Agriculture and Food Research Initiative Competitive Grant 2011-67015-20067 and National Needs Fellowship Grant 2010-38420-20397. The University of Nebraska Microarray core receives partial support from the National Center for Research Resources (5P20RR-016469, RR-018788-08) and the National Institute for General Medical Science (NIGMS) (8P20GM-103471, GM-103471-09). This publication’s contents are the sole responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or NIGMS.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES


Physiol Genomics • doi:10.1152/physiolgenomics.00082.2013 • www.physiolgenomics.org


